Newsroom

Download PDF Biogen Idec to Obtain Option to Commercialize ErbB3 Antibodies Outside of North America CAMBRIDGE, Mass., March 24, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced a definitive agreement with Biogen Idec, Inc. (NASDAQ:BIIB), for the development and

Download PDF Biogen Idec to Obtain Option to Commercialize ErbB3 Antibodies Outside of North America CAMBRIDGE, Mass., March 24, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced a definitive agreement with Biogen Idec, Inc. (NASDAQ:BIIB), for the development and

Download PDF Cambridge, Mass., March 23, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that Tuan Ha-Ngoc, president and chief executive officer, will present at InsideVenture’s Debut Conference, March 25-26, 2009 in Santa Barbara, California. AVEO has been selected

Download PDF CAMBRIDGE, Mass., March 11, 2009 – AVEO Pharmaceuticals, Inc. today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 29th Annual Health Care Conference on Wednesday, March 18, 2009 at 9:30 a.m. EDT at the Boston Marriott Copley Place in Boston, Mass. About AVEO

Download PDF CAMBRIDGE, Mass., March 10, 2009 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the initiation of a Phase 1b/2a clinical trial of AV-951 as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). This new trial

Download PDF CAMBRIDGE, Mass., March 6, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Barclays Global Healthcare Conference on Tuesday, March 10, 2009 at 4:15 p.m. (EDT) at the Loews Miami Beach Hotel in Miami, FL. About AVEO AVEO is a late-stage biopharmaceutical company

Download PDF 272-Patient Phase 2 Data Show 91.7 Percent Disease Control Rate and Favorable Tolerability; Interim Results Being Presented at ASCO GU Indicate Highly Differentiated VEGFR Profile CAMBRIDGE, Mass., February 25, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced

Download PDF CAMBRIDGE, Mass., February 19, 2009 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the initiation of a Phase 1b/2a clinical trial in breast cancer, expanding on the broad development program for its lead product candidate, the novel, oral